Promising phase II biologics for future Crohn's disease therapy.
Fiche publication
Date publication
mai 2023
Journal
Expert opinion on investigational drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Wils P, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Although the physician's therapeutic arsenal of Crohn's Disease (CD) is rapidly expanded over the next 25 years, a significant proportion of patients remain non-responders, or develop a loss of response or intolerance to current therapies, indicating a need for new therapeutic strategies in CD.
Mots clés
Crohn’s disease, Phase II, biologics, inflammatory bowel diseases, randomized trials
Référence
Expert Opin Investig Drugs. 2023 05 31;:1-13